The ERIS scheme offers a significant cash benefit—up to 27% of qualifying R&D costs—for loss-making SMEs. However, with the reduction in the intensity threshold to 30%, HMRC’s scrutiny of eligibility is higher than ever.
Don’t risk your claim on a manual assessment. Our expert team provides the rigorous technical and financial validation required to move your ERIS claim from "submitted" to "defensible.
Protect your client relationships with white-label-ready compliance support. We handle the complex aggregation calculations and intensity testing so you don't have to.
Ensure your 27% credit is audit-proof. We manage the R&D narrative and financial evidence, freeing you to focus on innovation.
Many businesses treat ERIS as a year-end compliance task. This is a primary cause of HMRC enquiries. Small shifts in staffing, group structure, or R&D spend can move you in or out of the 30% intensity threshold, leading to incorrect claims or disallowed expenditure.
We treat ERIS as a managed service, not a one-off filing. We help you:
Navigate Aggregation Rules: We calculate expenditure across worldwide linked and partner enterprises—a common pitfall that often leads to failed claims.
Bridge the RDEC/ERIS Gap: We perform a comparative analysis to determine if ERIS truly offers the best net benefit for your specific loss position, or if RDEC is the safer, more lucrative path.
Ensure Contemporaneous Compliance: We help you document technological uncertainty as it happens, ensuring your claim is built on evidence, not retroactive creative licence.
See case studies on some high-growth start-up firms we have helped secure their 27% credit.
The 30% Intensity Test: Requires global aggregation of income and expenditure. We specialise in mapping these structures.
The Loss-Making Test: We verify your trading losses, before the R&D claim to ensure the 27% credit is accurately applied.
Benefit Comparison: We don't assume ERIS is better; we calculate it against RDEC to guarantee you receive the maximum allowable cash credit.
Whether you need a second opinion on a current filing or full-service management for your annual claim, our advisors are ready to assist.
ERIS is part of the reformed UK R&D relief framework. It is aimed at innovative loss making SMEs that meet a higher-than-normal threshold of R&D activity, known as the R&D intensity test.
Qualifying companies can access a higher payable tax credit than under RDEC, making ERIS particularly valuable for early-stage or high-growth businesses with substantial R&D spend.
Loss-making SMEs that qualify for ERIS can claim up to 27% of their qualifying R&D costs as a cash credit.
By comparison, the RDEC scheme typically provides a benefit of around 15% to 16% of relevant expenditure.
The ERIS calculation is completed within the company’s tax computation.
To qualify for ERIS, a company must meet both of the following conditions for the relevant accounting period.
The tax computation of the UK claimant company only must show a trading loss before the R&D claim is applied.Group results do not affect this loss test.
A company must have spent at least 30% of its total expenditure on qualifying R&D during the accounting period.
For accounting periods beginning before 1 April 2024, the threshold is 40%.
For accounting periods beginning on or after 1 April 2024, the threshold reduces to 30%.
Important: Group Aggregation Applies
The intensity test is calculated using aggregated expenditure across all worldwide linked or partner enterprises. This means:
Overseas subsidiaries
Connected companies
Partner enterprises
…must all be included in the calculation of total income and total expenditure, even if they are outside the UK.
This is a common area of confusion and a frequent cause of incorrect eligibility assessments.
ERIS provides a payable tax credit of up to 27% of qualifying R&D costs, but the exact value depends on the relationship between:
the company’s trading loss (before the R&D claim), and
its qualifying R&D expenditure.
If the pre-claim loss is equal to or greater than the qualifying R&D spend, the company typically receives the maximum 27% benefit.
If the loss is smaller, the benefit percentage reduces, which may make RDEC more attractive.
Even if a company qualifies for ERIS, it is not always the best choice. In some cases, RDEC can deliver a higher benefit.
General rule of thumb:
If pre-claim trading losses ≥ qualifying R&D expenditure → ERIS usually gives the maximum 27%.
If pre-claim trading losses are less than 25% of qualifying R&D costs → RDEC is often more beneficial, despite ERIS eligibility.
A correct comparison should be performed within the tax computation for each accounting period.
Example
A company has total expenditure of £2m and qualifying R&D costs of £650k (intensity of 32.5% – so ERIS-eligible).
Its pre-claim loss is £150k.
Because the loss is significantly lower than the R&D spend, RDEC may give a higher net benefit than ERIS.
This illustrates why a comparative calculation is essential.
Calculating R&D intensity using only UK claimant company figures instead of including global holdings.
Not adjusting for partner/linked enterprise rules.
Assuming ERIS is always better than RDEC.
Failing to test if there were losses before the R&D credit impact is calculated.
Misunderstanding what counts as “total expenditure” for intensity purposes.
ERIS offers up to 27% of qualifying R&D costs as a cash credit for loss-making SMEs.
The 30% R&D intensity test applies from April 2024 and must consider worldwide group expenditure.
The loss test applies only to the UK claimant company.
ERIS is not always more beneficial than RDEC — the best option depends on the company’s loss position.
We can model both scenarios to calculate the maximum allowable benefit and ensure your claim is accurate, compliant, and optimised - get in touch.